Short-term Efficacy of 125I Radioactive Particles in the Treatment of Elderly Patients with Oral Squamous Cell Carcinoma
Oral squamous cell carcinoma is the most common malignant tumor in oral and maxillofacial region. Radiation as a clinical treatment for OSCC, its side effects such as tumor treatment resistance or malignant transformation are getting more and more attention. This article explores the feasibility, short-term efficacy and adverse reactions of 125I radioactive seed implantation in the treatment of elderly patients with oral cancer. The elderly patients with oral cancer were selected. The tumor site included the tongue, the bottom of the mouth, the upper jaw, the buccal and the parapharynx. The diameter of the tumor was 3 to 9 cm. CT-guided 125I radioactive seed implantation combined with nimotuzumab was administered. On average, 32.5 granules were implanted in each patient, and CT was performed immediately after surgery, 3 months, and 6 months, followed up for 8 months to 20 months. The results showed that the total effective rate of treatment was 84%. The main adverse reactions included leukopenia, nausea, vomiting, local bleeding, radiation mucositis, etc. There were no serious radiation damage and acute complications during the treatment. 125I radioactive seed implantation combined with nimotuzumab for the treatment of inoperable advanced head and neck squamous cell carcinoma is minimally invasive, effective, easy to operate, and safe.